Ap19
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) |
Société Générale S.A. |
| Company dealt in |
Allergan plc |
| Class of relevant security to which the dealings being disclosed relate (Note 2) |
US$0.0001 ordinary shares |
| Date of dealing |
21/04/2020 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long |
Short |
||
| Number |
(%) |
Number |
(%) |
|
| (1) Relevant securities |
2,977,854 |
0.90 |
45,208 |
0.01 |
| (2) Derivatives (other than options) |
0 |
0.00 |
**2,696,913 |
0.82 |
| (3) Options and agreements to purchase/sell |
58,500 |
0.02 |
0 |
0.00 |
| Total |
*7,176,929 |
*2.18 |
2,742,121 |
0.83 |
* Include the holding of 4,140,575 shares on borrow products
**The change in the holding of 841,400 shares is due to a derivative which is referenced to a basket of securities becoming to be disclosable for the purpose of the code
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: |
Long |
Short |
||
|
|
Number |
(%) |
Number |
(%) |
| (1) Relevant securities |
|
|
|
|
| (2) Derivatives (other than options) |
|
|
|
|
| (3) Options and agreements to purchase/sell |
|
|
|
|
| Total |
|
|
|
|
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale |
Number of relevant securities |
Price per unit USD (Note 5) |
| Purchase |
300 |
184.84 |
| Purchase |
193 |
184.059378 |
| Purchase |
47 |
184.061702 |
| Purchase |
2,125 |
184.04 |
| Purchase |
970 |
184.04 |
| Purchase |
305 |
184.472951 |
| Purchase |
48 |
184.6 |
| Purchase |
100 |
184.47 |
| Purchase |
100 |
184.89 |
| Purchase |
100 |
185.84 |
| Purchase |
100 |
185.68 |
| Purchase |
100 |
184.45 |
| Purchase |
1,576 |
184.04 |
| Purchase |
49 |
184.562 |
| Sale |
99 |
184.35 |
| Sale |
24 |
184.37 |
| Sale |
315 |
186.088889 |
| Sale |
37 |
184.04 |
| Sale |
358 |
186.01067 |
| Sale |
77 |
185.55 |
| Sale |
23 |
185.55 |
| Sale |
100 |
184.47 |
| Sale |
100 |
184.13 |
| Sale |
2,079 |
185.688576 |
| Sale |
100 |
184.34 |
| Sale |
100 |
184.28 |
| Sale |
100 |
184.88 |
| Sale |
100 |
185.65 |
| Sale |
100 |
184.58 |
| Sale |
100 |
184.61 |
| Sale |
100 |
184.46 |
| Sale |
100 |
184.33 |
| Sale |
7 |
184.38 |
| Sale |
100 |
186.15 |
| Sale |
100 |
185.58 |
| Sale |
16 |
184.22 |
| Sale |
60 |
184.23 |
| Sale |
90 |
185.8 |
| Sale |
10 |
185.8 |
| Sale |
100 |
184.91 |
| Sale |
61 |
184.65 |
| Sale |
39 |
184.65 |
| Sale |
89 |
184.44 |
| Sale |
98 |
184.56 |
| Sale |
2 |
184.56 |
| Sale |
100 |
184.36 |
| Sale |
2 |
184.42 |
| Sale |
98 |
184.42 |
| Sale |
100 |
184.48 |
| Sale |
100 |
184.58 |
| Sale |
100 |
184.49 |
| Sale |
100 |
184.64 |
| Sale |
2 |
184.65 |
| Sale |
98 |
184.65 |
| Sale |
100 |
185.23 |
| Sale |
100 |
184.36 |
| Sale |
100 |
184.6 |
| Sale |
100 |
184.41 |
| Sale |
100 |
184.33 |
| Sale |
100 |
185.66 |
| Sale |
100 |
184.48 |
| Sale |
14 |
184.14 |
| Sale |
6 |
184.14 |
| Sale |
94 |
184.14 |
| Sale |
100 |
186.1 |
| Sale |
100 |
184.64 |
| Sale |
100 |
184.66 |
| Sale |
100 |
184.76 |
| Sale |
100 |
185.01 |
| Sale |
100 |
184.27 |
| Sale |
100 |
184.62 |
| Sale |
100 |
184.62 |
| Total Purchases |
6,113 |
|
| Total Sales |
7,098 |
|
(b) Derivatives transactions (other than options transactions)
| Product name, e.g. CFD |
Nature of transaction (Note 6) |
Number of relevant securities (Note 7) |
Price per unit USD (Note 5) |
|
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
|
(ii) Exercising
| Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
|
|
|
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating to the voting rights of any relevant securities under any option referred to
on this form or relating to the voting rights or future acquisition or disposal of any relevantsecurities
to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) Yes
| Date of disclosure |
22/04/2020 |
| Contact name |
Société Générale - Disclosure team |
| Telephone number |
+33 1 42 14 92 74 |
| If a connected EFM, name of offeree/offeror with which connected |
|
| If a connected EFM, state nature of connection (Note 10) |
|
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name, e.g. call option |
Written, or purchased |
Number of relevant securities to which the option or derivative relates |
Exercise price (Note 2) |
Type, e.g. American, European etc. |
Expiry date |
| Listed Put Option |
Sale |
40,000 |
175 |
American options |
15/01/2021 |
| Listed Put Option |
Sale |
18,500 |
190 |
American options |
15/01/2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should
be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the
Rules. If in doubt, consult the Panel.